These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 1802683)
21. Alterations in glucose metabolism in the elderly patient with diabetes. Meneilly GS; Dawson K; Tessier D Diabetes Care; 1993 Sep; 16(9):1241-8. PubMed ID: 8404427 [TBL] [Abstract][Full Text] [Related]
22. NIDDM in the elderly. Meneilly GS; Elliott T; Tessier D; Hards L; Tildesley H Diabetes Care; 1996 Dec; 19(12):1320-5. PubMed ID: 8941457 [TBL] [Abstract][Full Text] [Related]
23. Impact of obesity on insulin action in NIDDM. Campbell PJ; Carlson MG Diabetes; 1993 Mar; 42(3):405-10. PubMed ID: 8432411 [TBL] [Abstract][Full Text] [Related]
24. Reduced glucose-induced thermogenesis is present in noninsulin-dependent diabetes mellitus without obesity. Gumbiner B; Thorburn AW; Henry RR J Clin Endocrinol Metab; 1991 Apr; 72(4):801-7. PubMed ID: 2005204 [TBL] [Abstract][Full Text] [Related]
25. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. Kudolo GB; Bressler P; DeFronzo RA J Lipid Mediat Cell Signal; 1997 Nov; 17(2):97-113. PubMed ID: 9459136 [TBL] [Abstract][Full Text] [Related]
26. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Kruszynska YT; Mulford MI; Baloga J; Yu JG; Olefsky JM Diabetes; 1998 Jul; 47(7):1107-13. PubMed ID: 9648835 [TBL] [Abstract][Full Text] [Related]
27. Estimates of insulin action in normal, obese and NIDDM man: comparison of insulin and glucose infusion test, CIGMA, minimal model and glucose clamp techniques. Davis SN; Monti L; Piatti PM; Moller N; Ng L; Coppack S; May M; Brown MD; Orskov H; Alberti KG Diabetes Res; 1993; 23(1):1-18. PubMed ID: 7924144 [TBL] [Abstract][Full Text] [Related]
28. Obesity, type 2 diabetes, and impaired insulin-stimulated blood flow: role of skeletal muscle NO synthase and endothelin-1. Reynolds LJ; Credeur DP; Manrique C; Padilla J; Fadel PJ; Thyfault JP J Appl Physiol (1985); 2017 Jan; 122(1):38-47. PubMed ID: 27789766 [TBL] [Abstract][Full Text] [Related]
30. Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Dela F; Larsen JJ; Mikines KJ; Ploug T; Petersen LN; Galbo H Diabetes; 1995 Sep; 44(9):1010-20. PubMed ID: 7657022 [TBL] [Abstract][Full Text] [Related]
31. Poor physical fitness, and impaired early insulin response but late hyperinsulinaemia, as predictors of NIDDM in middle-aged Swedish men. Eriksson KF; Lindgärde F Diabetologia; 1996 May; 39(5):573-9. PubMed ID: 8739917 [TBL] [Abstract][Full Text] [Related]
32. Whole-body glucose metabolism in obese patients with type 2 diabetes mellitus: the impact of hypertension and strict blood glucose control. Vestergaard H; Parving HH; Hansen L; Pedersen O Diabet Med; 1995 Feb; 12(2):156-63. PubMed ID: 7743763 [TBL] [Abstract][Full Text] [Related]
33. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019 [TBL] [Abstract][Full Text] [Related]
34. In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Chun KH; Choi KD; Lee DH; Jung Y; Henry RR; Ciaraldi TP; Kim YB Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E536-42. PubMed ID: 21189360 [TBL] [Abstract][Full Text] [Related]
35. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Frias JP; Yu JG; Kruszynska YT; Olefsky JM Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970 [TBL] [Abstract][Full Text] [Related]
36. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Felber JP; Ferrannini E; Golay A; Meyer HU; Theibaud D; Curchod B; Maeder E; Jequier E; DeFronzo RA Diabetes; 1987 Nov; 36(11):1341-50. PubMed ID: 3311856 [TBL] [Abstract][Full Text] [Related]
37. Glucose disposal in obese non-diabetic and diabetic type II patients. A study by indirect calorimetry and euglycemic insulin clamp. Golay A; Defronzo RA; Thorin D; Jequier E; Felber JP Diabete Metab; 1988; 14(4):443-51. PubMed ID: 3066652 [TBL] [Abstract][Full Text] [Related]
38. Cellular mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Olefsky JM; Garvey WT; Henry RR; Brillon D; Matthaei S; Freidenberg GR Am J Med; 1988 Nov; 85(5A):86-105. PubMed ID: 3057897 [TBL] [Abstract][Full Text] [Related]
39. Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance. Kruszynska YT; Olefsky JM; Frias JP Metabolism; 2003 Feb; 52(2):233-8. PubMed ID: 12601639 [TBL] [Abstract][Full Text] [Related]
40. Intracellular defects in glucose metabolism in obese patients with NIDDM. Kelley DE; Mokan M; Mandarino LJ Diabetes; 1992 Jun; 41(6):698-706. PubMed ID: 1587397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]